NCT06580106 Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML
| NCT ID | NCT06580106 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wake Forest University Health Sciences |
| Condition | Leukemia, Myeloid, Acute |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-04-09 |
| Primary Completion | 2027-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2025-04-09 with a primary completion date of 2027-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research is to see how certain genetic variations relate to side effects and outcomes experienced while receiving treatment with azacitidine and venetoclax.
Eligibility Criteria
Inclusion Criteria: * Written informed consent and HIPAA authorization for release of personal health information. * Age ≥ 18 years of age at the time of consent * Confirmed diagnosis of AML * Planned initial treatment with azacitidine and venetoclax * Ability to read and understand the English and/or Spanish language * As determined by the enrolling investigator, ability of the participant to understand and comply with study procedures for the entire length of the study Exclusion Criteria: * None
Contact & Investigator
Brittany Ragon, MD
PRINCIPAL INVESTIGATOR
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Frequently Asked Questions
Who can join the NCT06580106 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Leukemia, Myeloid, Acute. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06580106 currently recruiting?
Yes, NCT06580106 is actively recruiting participants. Contact the research team at courtney.schepel@advocatehealth.org for enrollment information.
Where is the NCT06580106 trial being conducted?
This trial is being conducted at Charlotte, United States, Winston-Salem, United States.
Who is sponsoring the NCT06580106 clinical trial?
NCT06580106 is sponsored by Wake Forest University Health Sciences. The principal investigator is Brittany Ragon, MD at Atrium Health Wake Forest Baptist Comprehensive Cancer Center. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.